Johan Vingerhoets

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2007 · 515 citations

Treatment-experienced Hiv-1-infected Patients, Treatment And Prevention, Human Retrovirus +11

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Adriano Lazzarin, Thomas Campbell, Bonaventura Clotet et al. · The Lancet · 2007 · 392 citations

Treatment-experienced Hiv-1-infected Patients, Treatment And Prevention, Human Retrovirus +11

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans et al. · Antimicrobial Agents and Chemotherapy · 2004 · 322 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +17

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Hilde Azijn, Ilse Tirry, Johan Vingerhoets et al. · Antimicrobial Agents and Chemotherapy · 2009 · 291 citations · Full text

Hiv-1 Group M, Medicine, Human Retrovirus +15

TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments

Johan Vingerhoets, Hilde Azijn, Els Fransen et al. · Journal of Virology · 2005 · 246 citations · Full text